11. Female and male patients of reproductive potential must be willing to use an adequate method of contraception, for the first year of the trial and if randomised to pembrolizumab, for the duration of treatment through to 120 days after the last dose of pembrolizumab. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.